Foghorn Therapeutics (FHTX) Net Income towards Common Stockholders (2020 - 2025)
Historic Net Income towards Common Stockholders for Foghorn Therapeutics (FHTX) over the last 6 years, with Q3 2025 value amounting to -$16.5 million.
- Foghorn Therapeutics' Net Income towards Common Stockholders rose 1387.41% to -$16.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$75.0 million, marking a year-over-year increase of 1780.47%. This contributed to the annual value of -$86.6 million for FY2024, which is 1199.48% up from last year.
- According to the latest figures from Q3 2025, Foghorn Therapeutics' Net Income towards Common Stockholders is -$16.5 million, which was up 1387.41% from -$18.8 million recorded in Q2 2025.
- In the past 5 years, Foghorn Therapeutics' Net Income towards Common Stockholders ranged from a high of -$14.3 million in Q3 2023 and a low of -$30.5 million during Q1 2023
- Over the past 5 years, Foghorn Therapeutics' median Net Income towards Common Stockholders value was -$24.1 million (recorded in 2023), while the average stood at -$23.8 million.
- As far as peak fluctuations go, Foghorn Therapeutics' Net Income towards Common Stockholders crashed by 6890.29% in 2021, and later skyrocketed by 4433.23% in 2023.
- Quarter analysis of 5 years shows Foghorn Therapeutics' Net Income towards Common Stockholders stood at -$28.5 million in 2021, then dropped by 1.33% to -$28.9 million in 2022, then increased by 16.55% to -$24.1 million in 2023, then increased by 19.09% to -$19.5 million in 2024, then increased by 15.56% to -$16.5 million in 2025.
- Its Net Income towards Common Stockholders was -$16.5 million in Q3 2025, compared to -$18.8 million in Q2 2025 and -$20.2 million in Q1 2025.